Skip to Main Content

The Institute for Clinical and Economic Review, ICER, a nonprofit that has become a central player in the debate over drug prices by doing its own analyses of what medicines are worth, is partnering with Aetion, a startup that analyzes insurance claims and other data mostly for pharmaceutical companies.

The partnership will try to use Aetion’s tools to help ICER make better decisions in creating its cost-effectiveness analyses of new medicines.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!